This course provides an overview of T-DXd reimbursement updates in Taiwan, specifically for HER2+ 2L metastatic breast cancer (mBC) patients and HER2-low, HR- mBC patients under NHIA coverage. It covers policy changes, clinical implications, and eligibility criteria. Additionally, the course highlights T-DXd’s strong efficacy while maintaining a manageable safety profile as an ADC therapy. The session will also explore key adverse event (AE) management strategies, including the prevention and management of nausea and vomiting using three types of antiemetics for high-emetic-risk drugs, and the prevention and management of interstitial lung disease (ILD). The focus will be on proactive monitoring, early intervention, and best practices to optimize patient outcomes.